New hope for rare brain disease: platform trial launches
NCT ID NCT07173803
First seen Nov 01, 2025 · Last updated May 16, 2026 · Updated 31 times
Summary
This study tests several experimental treatments for progressive supranuclear palsy (PSP), a rare brain disease that affects movement and thinking. About 440 people with early-stage PSP will join this platform trial to see if any of the treatments can slow the disease. The goal is to find a safe and effective way to help people with PSP maintain their abilities longer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROGRESSIVE SUPRANUCLEAR PALSY (PSP) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.